New Immunotherapy Combination May Help Combat Ovarian Tumors
A therapeutic strategy that targets key tumor proteins shows promise for treating the most common subtype of ovarian cancer, according to a recent study led by OCRA grantee Duygu Ozmadenci, PhD, of the University of California, San Diego Moores Cancer Center. High-grade serous ovarian carcinoma (HGSOC) is the most common subtype of ovarian cancer, with approximately 75% of epithelial ovarian cancers … Continued